Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 2:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 937–960 of 1,652 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Schizophrenia Spectrum and Other Psychotic Disorders Clear all
Completed Phase 1 Interventional

A Study To Examine The Safety, Tolerability And Pharmacokinetics Of PF-04958242 In Psychiatrically Stable Subjects With Schizophrenia

NCT01518894
View directory record Official record
Conditions
Schizophrenia
Interventions
PF-04958242, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Nov 21, 2019 · Synced Oct 18, 2026, 2:24 AM EDT
Terminated Phase 2 Interventional Results available

A Pharmaco-imaging Approach to Predicting Social Functioning and Clinical Responses to Oxytocin Administration in Schizophrenia

NCT03900754
View directory record Official record
Conditions
Schizophrenia
Interventions
Oxytocin, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 70 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
San Francisco, California • West Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 18, 2026, 2:24 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

The Effects of ∆-9-THC and Naloxone in Humans

NCT01591629
View directory record Official record
Conditions
Healthy
Interventions
Naloxone, Delta-9-THC, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Oct 18, 2026, 2:24 AM EDT
Withdrawn Phase 2Phase 3 Interventional

Sodium Butyrate For Improving Cognitive Function In Schizophrenia

NCT02654405
View directory record Official record
Conditions
Schizophrenic Disorders, Cognitive Function
Interventions
Sodium Butyrate, Placebo
Dietary Supplement · Other
Lead sponsor
Nathan Kline Institute for Psychiatric Research
Other
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Orangeburg, New York
Source: ClinicalTrials.gov public record
Updated Aug 15, 2016 · Synced Oct 18, 2026, 2:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, and Pharmacokinetics Study of Elpipodect (MK-8189) in Participants With Schizophrenia and Healthy Participants (MK-8189-011)

NCT04506905
View directory record Official record
Conditions
Schizophrenia
Interventions
Elpipodect, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
6
States / cities
Rogers, Arkansas • Glendale, California • Long Beach, California + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 18, 2026, 2:24 AM EDT
Completed Not applicable Interventional Results available

Improving Negative Symptoms of Psychosis In Real-world Environments

NCT02170051
View directory record Official record
Conditions
Schizophrenia
Interventions
CBSST-CCT, Goal focused supportive contact
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Oct 18, 2026, 2:24 AM EDT
Completed Phase 4 Interventional Results available

Varenicline for Cognitive Deficits and Cigarette Smoking in Schizophrenia - Efficacy and Predictors

NCT00802919
View directory record Official record
Conditions
Schizophrenia, Cigarette Smoking
Interventions
Varenicline, Placebo for varenicline
Drug
Lead sponsor
Nathan Kline Institute for Psychiatric Research
Other
Eligibility
18 Years to 65 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
2
States / cities
New York, New York • Orangeburg, New York
Source: ClinicalTrials.gov public record
Updated Dec 2, 2017 · Synced Oct 18, 2026, 2:24 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Striatal Connectivity and Clinical Outcome in Psychosis

NCT02822092
View directory record Official record
Conditions
Psychotic Disorders
Interventions
Risperidone or Aripiprazole (patients only)
Drug
Lead sponsor
Northwell Health
Other
Eligibility
15 Years to 40 Years
Enrollment
196 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2023
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Feb 21, 2024 · Synced Oct 18, 2026, 2:24 AM EDT
Completed Phase 1 Interventional Results available

A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Subjects With Schizophrenia

NCT02418819
View directory record Official record
Conditions
Schizophrenia
Interventions
PF-06412562 3mg BID, PF-06412562 9mg BID, PF-06412562 45mg BID, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 45 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
6
States / cities
Arcadia, California • Glendale, California • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2019 · Synced Oct 18, 2026, 2:24 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Social Cognition Assessment in Young Adults

NCT02922400
View directory record Official record
Conditions
Cognitive Function 1, Social
Interventions
Social Cognition Assessment and Training
Behavioral
Lead sponsor
The University of Texas at Dallas
Other
Eligibility
17 Years to 40 Years
Enrollment
153 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2018
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2018 · Synced Oct 18, 2026, 2:24 AM EDT
Not yet recruiting Phase 4 Interventional

Bromocriptine for Patients With Schizophrenia and Prediabetes

NCT03575000
View directory record Official record
Conditions
Schizophrenia, PreDiabetes
Interventions
Bromocriptine
Drug
Lead sponsor
VA Pittsburgh Healthcare System
Federal
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Oct 18, 2026, 2:24 AM EDT
Completed Not applicable Interventional Results available

Real-Time Mobile Cognitive Behavioral Intervention for Serious Mental Illness

NCT02035202
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder
Interventions
CBT2go, Smartphone
Behavioral · Device
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 55 Years
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 13, 2019 · Synced Oct 18, 2026, 2:24 AM EDT
Completed Phase 4 Interventional

The Effects of Aripiprazole on Patients With Metabolic Syndrome

NCT00224822
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Metabolic Syndrome X
Interventions
Aripiprazole
Drug
Lead sponsor
New Mexico VA Healthcare System
Federal
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Mar 24, 2010 · Synced Oct 18, 2026, 2:24 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Individualizing Incentives for Alcohol in the Severely Mentally Ill

NCT03481049
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder, Major Depressive Disorder, Alcohol Dependence
Interventions
Usual CM, High-Magnitude CM, Shaping CM
Behavioral
Lead sponsor
Washington State University
Other
Eligibility
18 Years to 65 Years
Enrollment
392 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
2
States / cities
Seattle, Washington • Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Oct 18, 2026, 2:24 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Intensive Computerized Brain Training (ICBT) in Youth With Early Onset Psychosis (EOP)

NCT01027962
View directory record Official record
Conditions
Psychosis
Interventions
ICBT Program
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
10 Years to 19 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 15, 2013 · Synced Oct 18, 2026, 2:24 AM EDT
Completed Not applicable Interventional Results available

Functional Rehabilitation of Older Patients With Schizophrenia

NCT00237796
View directory record Official record
Conditions
Psychotic Disorders, Schizoaffective Disorder, Schizophrenia
Interventions
Cognitive Behavioral Social Skills Training (CBSST), Goal Focused Supportive Contact (GFSC)
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
45 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Oct 18, 2026, 2:24 AM EDT
Completed Phase 4 Interventional Results available

Supported Employment and Skills Training in Conjunction With Pharmacotherapy in Schizophrenia Patients

NCT00183625
View directory record Official record
Conditions
Schizophrenia
Interventions
Individual Placement and Support (Supported Employment), Social Skills Training, Olanzapine, Risperidone
Behavioral · Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 60 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
2
States / cities
Los Angeles, California • Manchester, New Hampshire
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 18, 2026, 2:24 AM EDT
Completed Not applicable Interventional

Exploratory Study of a Digital Therapeutics in People With Schizophrenia

NCT05438160
View directory record Official record
Conditions
Schizophrenia
Interventions
Clinical Learning Study smartphone app (i.e., the study app)
Device
Lead sponsor
Click Therapeutics, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
7
States / cities
Anaheim, California • Torrance, California • Hialeah, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Oct 18, 2026, 2:24 AM EDT
Completed Not applicable Interventional Results available

Improving Cognition in Schizophrenia Using tDCS

NCT02539797
View directory record Official record
Conditions
Schizophrenia
Interventions
tDCS
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 55 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 7, 2018 · Synced Oct 18, 2026, 2:24 AM EDT
Recruiting Phase 2 Interventional

A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis

NCT06887192
View directory record Official record
Conditions
Psychosis Associated With Alzheimer's Disease
Interventions
ML-007C-MA, Placebo
Drug
Lead sponsor
MapLight Therapeutics
Industry
Eligibility
55 Years to 90 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
37
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 18, 2026, 2:24 AM EDT
Completed Not applicable Interventional

A Placebo-Controlled Study of Physiologic Effects of L-methylfolate in Schizophrenia Patients

NCT01091506
View directory record Official record
Conditions
Schizophrenia
Interventions
Placebo, L-methylfolate
Other
Lead sponsor
Pamlab, Inc.
Industry
Eligibility
18 Years to 68 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 3, 2016 · Synced Oct 18, 2026, 2:24 AM EDT
Completed Phase 2 Interventional Results available

A Multicenter Study of NAP (AL-108) in Schizophrenia

NCT00505765
View directory record Official record
Conditions
Schizophrenia
Interventions
AL-108, Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 60 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
8
States / cities
Los Angeles, California • Catonsville, Maryland • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2017 · Synced Oct 18, 2026, 2:24 AM EDT
Active, not recruiting Phase 3 Interventional

Treating Schizophrenia by Correcting Abnormal Brain Development

NCT00179465
View directory record Official record
Conditions
Schizophrenia
Interventions
Tiagabine, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 25 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Oct 18, 2026, 2:24 AM EDT
Completed Not applicable Interventional Results available

A Brief Community Linkage Intervention for Dually Diagnosed Individuals

NCT00137267
View directory record Official record
Conditions
Schizophrenia, Psychotic Disorders, Substance-Related Disorders, Bipolar Disorder
Interventions
Time limited case management, Health Education
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
2
States / cities
Bedford, Massachusetts • East Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated May 15, 2015 · Synced Oct 18, 2026, 2:24 AM EDT